Clinical Trial Detail

NCT ID NCT03147287
Title Palbociclib After CDK and Endocrine Therapy (PACE)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements yes
Sponsors Dana-Farber Cancer Institute
Indications

Her2-receptor negative breast cancer

Therapies

Palbociclib

Fulvestrant + Palbociclib

Avelumab + Fulvestrant + Palbociclib

Fulvestrant

Age Groups: adult senior

Additional content available in CKB BOOST